Evolution Summit By Marcus Evans | May 7-8, 2026 | The Ritz-Carlton, Fort Lauderdale, Florida

Why It Matters

By gathering the industry’s decision‑makers around decentralized trial strategies, the summit accelerates adoption of operational innovations that can shorten drug‑development timelines and reduce costs.

Key Takeaways

• Invitation‑only summit gathers top clinical trial decision makers
• Focus on decentralized trials and operational efficiency
• Keynotes from Decentralized Trials Alliance and Johnson & Johnson
• Executives from BMS, Bayer, BioNTech participating
• Interactive forums address real‑world drug development challenges

Pulse Analysis

The clinical‑trial ecosystem is at a crossroads, with sponsors seeking faster, more patient‑centric approaches to bring therapies to market. Decentralized trials, digital data capture, and adaptive designs have moved from pilot projects to mainstream expectations, driven by regulatory encouragement and heightened competition. Companies that master these innovations can cut study timelines, lower enrollment costs, and improve data quality, positioning themselves ahead of peers in an increasingly crowded pipeline landscape.

Against this backdrop, the Evolution Summit by Marcus Evans offers a premium platform for senior leaders to exchange insights and benchmark best practices. Hosted at the Ritz‑Carlton in Fort Lauderdale, the two‑day event blends high‑level keynotes—featuring Craig Lipset of the Decentralized Trials & Research Alliance and Laura Vessey from Johnson & Johnson Innovative Medicine—with deep‑dive case studies from industry heavyweights such as Bristol Myers Squibb, Bayer, and BioNTech. The invitation‑only format ensures focused dialogue, while interactive forums enable participants to explore real‑world challenges, from patient recruitment to data integration, in a collaborative setting.

The summit’s impact extends beyond knowledge transfer; it creates strategic networking opportunities that can catalyze partnerships between sponsors, technology providers, and CROs. As the sector pivots toward hybrid and fully virtual trial models, insights gained at Evolution will inform investment decisions, operational roadmaps, and regulatory strategies. Attendees leave equipped with actionable frameworks to accelerate trial execution, ultimately delivering innovative medicines to patients more efficiently and reinforcing the industry’s commitment to scientific advancement.